On 25 June, the commission reported that CIRM's governance structure "locks in inefficiencies" and "inhibits CIRM's ability to adjust to changing scientific and political landscapes". The commission recommended that CIRM downsize its board to 15 members, add members without ties to CIRM grantees, boost the efficiency and transparency of grant reviews, clarify the overlapping roles of chair and president, and "create succession plans for board leadership", a reference to Klein's statement that he will leave the agency next year.
Hall says the recommendations are "useful, thoughtful and should be seriously considered", but says "the leadership of the agency has taken a position that any change at all threatens the entirety of stemcell research, and that's unfortunate". Indeed, CIRM said in a statement that it was disappointed with the Little Hoover Commission's recommendations, which would "slow the agency's progress toward cures". But CIRM board member Jeff Sheehy wrote on a blog that CIRM's "knee jerk" reaction, delivered in a statement dated 24 June -before the Hoover group released its final report -"suggests a renegade agency outside the control of its board or the state of California".
The report is unlikely to spur immediate change, as the state legislature, which would need to enact many of the recommendations, is preoccupied with California's budget crisis. 
